Pharma Value developed a Comparison of marketing authorisations issued by the FDA and EMA in 2023.

The objective of the analysis is to provide a contextual view of the two agencies in their respective US and European markets.

In the report below you will learn more about:

• differences between drugs for rare diseases that have orphan designation,
• analysis of therapeutic areas of authorised drugs,
• focus on companies with marketing authorisation.